BioVie Inc. (BIVI) stock
BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
$1.00−0.08 (-7.84%)
Close on Nov 17, 2026Market cap $7.51MP/E –Yield –
BioVie EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
BioVie's EPS for the twelve months ending Jun 30, 2026 was -$3.05. For fiscal 2026 it was -$3.05. The highest annual figure on record is $0.00 in fiscal 2013.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$3.05 | – |
| FY2025 | Jun 30, 2025 | -$12.12 | – |
| FY2024 | Jun 30, 2024 | -$73.05 | – |
| FY2023 | Jun 30, 2023 | -$15.47 | – |
| FY2022 | Jun 30, 2022 | -$1.06 | – |
| FY2021 | Jun 30, 2021 | -$14.82 | – |
| FY2020 | Jun 30, 2020 | -$6.85 | – |
| FY2019 | Jun 30, 2019 | -$0.98 | – |
| FY2018 | Jun 30, 2018 | -$3.75 | – |
| FY2017 | Jun 30, 2017 | -$1.25 | – |
| FY2016 | Jun 30, 2016 | $0.00 | – |
| FY2015 | Jun 30, 2015 | $0.00 | – |
| FY2014 | Jun 30, 2014 | $0.00 | – |
| FY2013 | Jun 30, 2013 | $0.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$0.71 | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$0.70 | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$0.77 | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$0.98 | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$1.51 | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$4.55 | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$7.00 | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$2.00 | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$2.20 | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$2.92 | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$0.43 | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$0.50 | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$0.38 | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$0.32 | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$0.28 | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$0.22 | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$0.23 | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$8.32 | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$0.22 | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$0.22 | -117.1% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$7.75 | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$3.68 | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$0.07 | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $1.29 | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$5.06 | – |
| Q1 FY2019CQ3 2018 | Dec 31, 2018 | -$0.40 | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$0.73 | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$1.25 | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$1.25 | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$1.25 | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $0.00 | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $0.00 | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?